Recent advances in the systemic management of colorectal cancer

Bibliography

• 1  Toms JR (Ed.): Cancer Stats Monograph 2004. Cancer Research UK, London, UK (2004).
  Google Scholar
• 2  Gill S, Loprinzi CL, Sargent DJ et al.: Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and III colon cancer: who benefits and by how? J. Clin. Oncol.17,3553–3559 (1999).
  MedlineGoogle Scholar
• 3  Moertel CG, Fleming TR, Macdonald JS et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for Stage II/Dukes’ B2 colon cancer. J. Clin. Oncol.13,2936–2943 (1995).
  Medline CASGoogle Scholar
• 4  Gray RG, Barnwell J, Hills R et al.: QUASAR: a randomised study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc. Am. Soc. Clin. Oncol.22,245 A3501 (2004).
  Google Scholar
• 5  Poplin E, Benedetti J, Estes N et al.: Phase III randomised trial of bolus 5HFU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153). Proc. Am. Soc. Clin. Oncol.19,A931 (2000).
  Google Scholar
• 6  Saini A, Norman AR, Cunningham D et al.: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br. J. Cancer88,1859–1865 (2003).
  Medline CASGoogle Scholar
• 7  Cassidy J, Scheithauer W, McKendrick J et al.: Capecitabine vs bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a Phase III trial. J. Clin. Oncol.22(Suppl.) 3509 (2004).
  Google Scholar
• 8  Saltz LB, Niedzwiecki D, Hollis D et al.: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil alone (FL) in Stage III colon cancer (intergroup trial CALGB C89803). J. Clin. Oncol.22(Suppl.),3500 (2004).
  Google Scholar
• 9  Andre T, Boni C, Mounedji-Boudiaf L et al.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N. Eng. J. Med.350,2343–2351 (2004).
  Medline CASGoogle Scholar
• 10  Barrat PL, Seymour MT, Stenning SP et al.: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet360,1381–1391. (2002).
  MedlineGoogle Scholar
• 11  Al-Mulla F, Behbehani AI, Bitar MS, Varadharaj G, Going JJ: Genetic profiling of Stage I and II colorectal cancer may predict metastatic relapse. Mod. Pathol.19,648–658. (2006).
  Google Scholar
• 12  Cunningham D, Pyrhonen S, James RD et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet352,1413–1418 (1998).
  Medline CASGoogle Scholar
• 13  Rougier P, Van Custem E, Bajetta E et al.: Randomised trial of irinotecan versus flourouracil by continouus infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet352,1407–1412 (1998).
  Medline CASGoogle Scholar
• 14  Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343,905–914 (2000).
  Medline CASGoogle Scholar
• 15  Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet355,1041–1047 (2000).
  Medline CASGoogle Scholar
• 16  Rothenberg ML, Meropol NJ, Poplin EA et al.: Mortality associated with irinotecan plus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol.19,3801–3807 (2001).
  Medline CASGoogle Scholar
• 17  Hwang JJ, Eisenberg SG, Marshall JL: Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology17(Suppl. 8),37–43 (2003).
  MedlineGoogle Scholar
• 18  Becouarn Y, Ychou M, Ducreux M et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J. Clin. Oncol.16,2739–2744 (1998).
  Medline CASGoogle Scholar
• 19  Diaz-Rubio E, Sastre J, Zaniboni A et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol.9,105–108 (1998).
  Medline CASGoogle Scholar
• 20  de Gramont A, Figer A, Seymour M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18,2938–2947 (2000).
  Medline CASGoogle Scholar
• 21  Giacchetti S, Perpoint B, Zidani R et al.: Phase III muticenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.18,136–147 (2000).
  Medline CASGoogle Scholar
• 22  Rothenberg ML, Oza AM, Bigelow RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol.21,2059–2069 (2003).
  Medline CASGoogle Scholar
• 23  de Gramont A, Bosset JF, Milan C et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol.15,808–815 (1997).
  Medline CASGoogle Scholar
• 24  Adam R, Avisar E, Ariche A et al.: Five year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann. Surg. Oncol. 8,347–353 (2000).
  Google Scholar
• 25  Hoff PM, Ansari R, Batist G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19,2282–2292 (2001).
  Medline CASGoogle Scholar
• 26  van Cutsem E, Twelves C, Cassidy J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large Phase III study. J. Clin. Oncol.19,4097–4106 (2001).
  Medline CASGoogle Scholar
• 27  Twelves C: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, Phase III trials. Eur. J. Cancer38,15–20 (2002).
  MedlineGoogle Scholar
• 28  Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leocovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22,23–30 (2004).
  Medline CASGoogle Scholar
• 29  Souglakos J, Androulakis N, Syrigos K et al.: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and ironotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group. Br. J. Cancer94,798–805 (2006).
  Medline CASGoogle Scholar
• 30  Tournigand C, Andre T, Achille E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22,229–237 (2004).
  Medline CASGoogle Scholar
• 31  Grothey A, Jordan K, Kellner O et al.: Randomized Phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Prog. Proc. Am. Soc. Clin. Oncol.22,255 (2003).
  Google Scholar
• 32  Grothey A, Sargent D, Goldberg RM et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol.22,1209–1214 (2004).
  Medline CASGoogle Scholar
• 33  Maindrault-Goebel F, Tournigand C, Andre T et al.: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol.15,1210–1214 (2004).
  Medline CASGoogle Scholar
• 34  de Gramont A, Cervantes A, Andre T et al.: OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol.22,251 A3525 (2004).
  Google Scholar
• 35  Hurwitz H, Fehrenbacher L, Cartwright T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol.22,A3646 (2003).
  Google Scholar
• 36  Hurwitz H, Fehrenbacher L Novotny W et al.: Bevacizumab (Avastin) plus irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer. N. Eng. J. Med.350,2335–2342 (2004).
  Medline CASGoogle Scholar
• 37  Cunningham D, Humblet Y, Siena S et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol.22(252),A1012 (2003).
  Google Scholar
• 38  Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Eng. J. Med.351,337–345 (2004).
  Medline CASGoogle Scholar
• 39  Kabbinavar F, Schulz J, McCleod M et al.: Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer in subjects who are not suitable for first-line CPT-11. J. Clin. Oncol.22(Suppl.),3516 (2004).
  Google Scholar
• 40  Giantonio BJ, Catalano PJ, Meropol NJ et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from Eastern Cooperative Group (ECOG) study E2300. Proceedings of: the 2005 Gastrointestinal Cancers Symposium. American Society of Clinical Oncology, Orlando, FL, USA, May 13–17 (2005).
  Google Scholar
• 41  Vincenzi B, Santini D, Rabitti C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer94,792–797 (2006).
  Medline CASGoogle Scholar
• 42  Steward W, Thomas A, Morgan B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.22(259),A2556 (2004).
  Google Scholar
• 43  Meyerhardt JA, Zhu AX, Enzinger PC et al.: Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J. Clin. Oncol.24,1892–1897 (2006).
  Medline CASGoogle Scholar